Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy

Tae In Wi; Yeongseon Byeon; Ji Eun Won; Jae Myeong Lee; Tae Heung Kang; Jeong Won Lee; Young Joo Lee; Anil K. Sood; Hee Dong Han; Yeong Min Park

doi:10.1166/jbn.2020.2883

Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy

Tae In Wi, Yeongseon Byeon, Ji Eun Won, Jae Myeong Lee, Tae Heung Kang, Jeong Won Lee, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong Min Park

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A key issue in dendritic cell (DC)-based cancer immunotherapy is the effective delivery of tumor-specific antigens to DCs. To deliver antigens, non-viral vaccine system has been used in ex vivo manipulation. However, ex vivo manipulation is time-consuming, lacks quality control of DCs, and demonstrates low antigen delivery efficiency, which implicates that there are serious problems in therapeutic DC preparations. Therefore, we developed mannose (MN)-labeled poly(d, l-lactide-co-glycolide) (PLGA) nanoparticles (MN-PLGA-NPs) encapsulating tumor-specific antigens for targeted delivery to mannose receptors (MN-R) on DC surfaces without ex vivo manipulation. The MN-PLGA-NPs showed DC-selective delivery in tumor-bearing mice, leading to highly mature and activated DCs, which migrated to lymphoid organs, resulting in activation of cytotoxic CD8+ T cells. Additionally, MN-PLGA-NPs showed significant therapeutic efficacy in EG7 lymphoma tumorbearing mice. Our nano-platform technology can be used as a vaccine system to bypass ex vivo manipulation and enhance targeted delivery of tumor-specific antigens to DCs, which is well-suited for cancer immunotherapy.

Original language	English (US)
Pages (from-to)	201-211
Number of pages	11
Journal	Journal of biomedical nanotechnology
Volume	16
Issue number	2
DOIs	https://doi.org/10.1166/jbn.2020.2883
State	Published - Feb 1 2020

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science
Pharmaceutical Science

Access to Document

10.1166/jbn.2020.2883

Cite this

Wi, T. I., Byeon, Y., Won, J. E., Lee, J. M., Kang, T. H., Lee, J. W., Lee, Y. J., Sood, A. K., Han, H. D., & Park, Y. M. (2020). Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy. Journal of biomedical nanotechnology, 16(2), 201-211. https://doi.org/10.1166/jbn.2020.2883

@article{ea838ac8c03e4eea8d057412859e3118,

title = "Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy",

abstract = "A key issue in dendritic cell (DC)-based cancer immunotherapy is the effective delivery of tumor-specific antigens to DCs. To deliver antigens, non-viral vaccine system has been used in ex vivo manipulation. However, ex vivo manipulation is time-consuming, lacks quality control of DCs, and demonstrates low antigen delivery efficiency, which implicates that there are serious problems in therapeutic DC preparations. Therefore, we developed mannose (MN)-labeled poly(d, l-lactide-co-glycolide) (PLGA) nanoparticles (MN-PLGA-NPs) encapsulating tumor-specific antigens for targeted delivery to mannose receptors (MN-R) on DC surfaces without ex vivo manipulation. The MN-PLGA-NPs showed DC-selective delivery in tumor-bearing mice, leading to highly mature and activated DCs, which migrated to lymphoid organs, resulting in activation of cytotoxic CD8+ T cells. Additionally, MN-PLGA-NPs showed significant therapeutic efficacy in EG7 lymphoma tumorbearing mice. Our nano-platform technology can be used as a vaccine system to bypass ex vivo manipulation and enhance targeted delivery of tumor-specific antigens to DCs, which is well-suited for cancer immunotherapy.",

author = "Wi, {Tae In} and Yeongseon Byeon and Won, {Ji Eun} and Lee, {Jae Myeong} and Kang, {Tae Heung} and Lee, {Jeong Won} and Lee, {Young Joo} and Sood, {Anil K.} and Han, {Hee Dong} and Park, {Yeong Min}",

year = "2020",

month = feb,

day = "1",

doi = "10.1166/jbn.2020.2883",

language = "English (US)",

volume = "16",

pages = "201--211",

journal = "Journal of biomedical nanotechnology",

issn = "1550-7033",

publisher = "American Scientific Publishers",

number = "2",

}

TY - JOUR

T1 - Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy

AU - Wi, Tae In

AU - Byeon, Yeongseon

AU - Won, Ji Eun

AU - Lee, Jae Myeong

AU - Kang, Tae Heung

AU - Lee, Jeong Won

AU - Lee, Young Joo

AU - Sood, Anil K.

AU - Han, Hee Dong

AU - Park, Yeong Min

PY - 2020/2/1

Y1 - 2020/2/1

N2 - A key issue in dendritic cell (DC)-based cancer immunotherapy is the effective delivery of tumor-specific antigens to DCs. To deliver antigens, non-viral vaccine system has been used in ex vivo manipulation. However, ex vivo manipulation is time-consuming, lacks quality control of DCs, and demonstrates low antigen delivery efficiency, which implicates that there are serious problems in therapeutic DC preparations. Therefore, we developed mannose (MN)-labeled poly(d, l-lactide-co-glycolide) (PLGA) nanoparticles (MN-PLGA-NPs) encapsulating tumor-specific antigens for targeted delivery to mannose receptors (MN-R) on DC surfaces without ex vivo manipulation. The MN-PLGA-NPs showed DC-selective delivery in tumor-bearing mice, leading to highly mature and activated DCs, which migrated to lymphoid organs, resulting in activation of cytotoxic CD8+ T cells. Additionally, MN-PLGA-NPs showed significant therapeutic efficacy in EG7 lymphoma tumorbearing mice. Our nano-platform technology can be used as a vaccine system to bypass ex vivo manipulation and enhance targeted delivery of tumor-specific antigens to DCs, which is well-suited for cancer immunotherapy.

AB - A key issue in dendritic cell (DC)-based cancer immunotherapy is the effective delivery of tumor-specific antigens to DCs. To deliver antigens, non-viral vaccine system has been used in ex vivo manipulation. However, ex vivo manipulation is time-consuming, lacks quality control of DCs, and demonstrates low antigen delivery efficiency, which implicates that there are serious problems in therapeutic DC preparations. Therefore, we developed mannose (MN)-labeled poly(d, l-lactide-co-glycolide) (PLGA) nanoparticles (MN-PLGA-NPs) encapsulating tumor-specific antigens for targeted delivery to mannose receptors (MN-R) on DC surfaces without ex vivo manipulation. The MN-PLGA-NPs showed DC-selective delivery in tumor-bearing mice, leading to highly mature and activated DCs, which migrated to lymphoid organs, resulting in activation of cytotoxic CD8+ T cells. Additionally, MN-PLGA-NPs showed significant therapeutic efficacy in EG7 lymphoma tumorbearing mice. Our nano-platform technology can be used as a vaccine system to bypass ex vivo manipulation and enhance targeted delivery of tumor-specific antigens to DCs, which is well-suited for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85083072098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083072098&partnerID=8YFLogxK

U2 - 10.1166/jbn.2020.2883

DO - 10.1166/jbn.2020.2883

M3 - Article

C2 - 32252881

AN - SCOPUS:85083072098

SN - 1550-7033

VL - 16

SP - 201

EP - 211

JO - Journal of biomedical nanotechnology

JF - Journal of biomedical nanotechnology

IS - 2

ER -

Selective Tumor-Specific Antigen Delivery to Dendritic Cells Using Mannose-Labeled Poly(d, l-lactide-co-glycolide) Nanoparticles for Cancer Immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this